Literature DB >> 6295957

Cell-mediated immunity against herpes simplex virus envelope, capsid, excreted, and crude antigens.

K O Kalimo, I A Joronen, V K Havu.   

Abstract

Cell-mediated immunity to herpes simplex virus envelope, capsid, excreted, and crude antigens was studied by in vitro lymphocyte stimulation tests during 198 recurrent attacks in 69 patients. Excreted antigen caused no blast transformation. Envelope and capsid antigen-induced lymphocyte stimulation was at the maximum 7 to 14 days postinfection, declining thereafter to a rather constant level in 1 to 2 months. The lowest levels were measured just a few days before a new attack. In persons with frequent relapses, the fluctuation was more rapid and stimulation index levels stayed higher, although no protective level seemed to exist. Cultures stimulated with the crude antigen in autologous serum showed rapid increases and declines in the stimulation index values, contrary to those grown in agamma serum, in which the stimulation level stayed rather constant up to 1 year postinfection.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6295957      PMCID： PMC347902          DOI： 10.1128/iai.39.1.24-28.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  22 in total

1.  Defective in vitro lymphoproliferative responses to herpes simplex virus in patients with frequently recurring herpes infections during the disease-free interval.

Authors:  H Kirchner; M Schwenteck; H Northoff; E Schöpf
Journal:  Clin Immunol Immunopathol       Date:  1978-11

2.  Synthesis of proteins in cells infected with herpesvirus. X. Proteins excreted by cells infected with herpes simplex virus, types 1 and 2.

Authors:  A S Kaplan; J S Erickson; T Ben-Porat
Journal:  Virology       Date:  1975-03       Impact factor: 3.616

3.  Cellular immunity and circulating antibody to herpes simplex virus in subjects with recurrent herpex simplex lesions and controls as measured by the mixed leukocyte migration inhibition test and complement fixation.

Authors:  R W Gange; A de Bats; J R Park; C M Bradstreet; E L Rhodes
Journal:  Br J Dermatol       Date:  1975-11       Impact factor: 9.302

4.  Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in patients with recurrent herpes labialis.

Authors:  Y H Thong; M M Vincent; S A Hensen; D A Fuccillo; M Rola-Pleszczynski; J A Bellanti
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

5.  Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis.

Authors:  R J O'Reilly; A Chibbaro; E Anger; C Lopez
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

6.  Effect of serum on human rosett-forming cells in fetuses and adult blood.

Authors:  J Wybran; M C Carr; H H Fudenberg
Journal:  Clin Immunol Immunopathol       Date:  1973-04

7.  Solid-phase radioimmunoassay of human immunoglobulin M and immunoglobulin G antibodies against herpes simplex virus type 1 capsid, envelope, and excreted antigens.

Authors:  K O Kalimo; R J Marttila; K Granfors; M K Viljanen
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

8.  Sequential changes in cell-mediated immune responses to herpes simplex virus after recurrent herpetic infection in humans.

Authors:  E J Shillitoe; J M Wilton; T Lehner
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

9.  Solid-phase radioimmunoassay of herpes simplex virus IgG and IgM antibodies.

Authors:  K O Kalimo; B R Ziola; M K Viljanen; K Granfors; P Toivanen
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

10.  Cellular and humoral immune responses to herpes simplex virus during and after primary gingivostomatitis.

Authors:  A Møller-Larsen; S Haahr; F T Black
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441
View more
  6 in total

1.  Variation in lymphoproliferative responses during recrudescent orofacial herpes simplex virus infections.

Authors:  J P Vestey; M Norval; S Howie; J Maingay; W A Neill
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  Human immune responses to herpes simplex virus, varicella-zoster and cytomegalovirus in vitro.

Authors:  S A Williamson; N Parish; J D Chambers; R A Knight
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

3.  CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.

Authors:  D M Koelle; M Schomogyi; C McClurkan; S N Reymond; H B Chen
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

5.  Association between HSV1 seropositivity and obesity: data from the National Health and Nutritional Examination Survey, 2007-2008.

Authors:  Zuzana Karjala; Diane Neal; James Rohrer
Journal:  PLoS One       Date:  2011-05-11       Impact factor: 3.240

6.  Lymphoproliferative responses in recrudescent orofacial herpetic infections.

Authors:  J P Vestey; M Norval; S E Howie
Journal:  J R Soc Med       Date:  1990-05       Impact factor: 18.000
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.